The therapeutic area head of Clinical Development and Medical Affairs, Metabolism, at Boehringer Ingelheim sat down with MD Mag to detail the post-hoc analysis of the renal-outcome trials.
The great thing about em you know ragout them it was a doable study right was a very well conduct a study and over 7,000 patients and as a result right not only we have great primary data but there was an opportunity to go back and keep learning from that data so one of the two studies that to analysis that we’re presenting here ad a are focused on meeting unmet
Needs and that is chronic kidney disease and heart failure so let me tell you about the first of the studies right what we know is that when we look at empa when we look at jarnia’s and the benefit on new onset or worsening of renal or kidney disease right the effects were independent of cardiovascular risk the baselines right in other words what we’re talking
About a 1c we were talking about lipids right what we’re talking about blood pressure independent that those risks were control or not the effect of jargons on chronic a disease was consistent was positive so that’s that’s one of the studies the second one is that we look at hospitalization for heart failure and cv death and a baseline we look at we really took
A look at the different risk to the patient we have from a low risk to high risk and whether the effect was consistent right for each of those patients and across the continuum and we observe fortunately that the effect to each other was consistent across you know whether whether you’re low risk we were high risk the effect on the the positive effect of reducing
The risk of hospitalization for heart failure and cv death was consistent now you would think why is this important you know renal disease but it’s it’s a big unmet need and 15 percent of the u.s. population you know this is a number one reason renal failure heart failure is also a big unmet need here in the us we have almost 6 million people and unfortunately
Is a disease that has a high morbidity and mortality so if you think about that 50 percent 5-0 of people that are diagnosed with heart failure will die within five years so as you can imagine you know it’s a big unmet need and in a way it’s very reassurance because as you know we you know this is as i clarify before this was the substudy post hoc studies after
Empirical results but in a way they’re very reassuring very informative because we are doing the cvi outcome studies for heart failure right and also for for kidney by the emperor program and the impact kidney program so in a way this is something really relevant for for the for the medical audience
Transcribed from video
Rogelio Braceras, MD: Jardiance's Results in the EMPA-REG OUTCOME Trial By HCPLive
